NCCN Guidelines for Patients: Ovarian Cancer
-
Upload
national-ovarian-cancer-coalition -
Category
Health & Medicine
-
view
366 -
download
4
Transcript of NCCN Guidelines for Patients: Ovarian Cancer
![Page 1: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/1.jpg)
NCCN Guidelines for Patients: Ovarian Cancer
Deborah K. Armstrong, M.D.NOCC Annual Conference
Baltimore, MDFebruary 2016
![Page 2: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/2.jpg)
NCCN• National Cooperative Cancer Network
– A not-for-profit alliance of 26 leading cancer centers– Develops clinical practice guidelines for patients and
clinicians• Continuously reassessed and updated
– Drug compendia based on guidelines– Oncology research program
• Original research utilizing the NCCN database• Sponsored research • Young investigator awards
– NCCN Foundation (philanthropic arm)
![Page 3: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/3.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 4: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/4.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 5: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/5.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 6: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/6.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 7: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/7.jpg)
Is the Ovary Really the Organ of Origin
for “Ovarian” Cancer?
![Page 8: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/8.jpg)
Fallopian Tube Origin of Ovarian Cancer• No precancerous lesions have been identified in
the ovary• Serous epithelium is seen in the FT, not in the
ovary – most advanced ovarian cancers are serous
• There are several logs more epithelial cells in the fallopian tube compared to the ovary
• Accumulation of pathologic changes in the FT reflect findings in “ovarian cancer”
![Page 9: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/9.jpg)
A. M. Karst and R. Drapkin J Oncol 2010
![Page 10: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/10.jpg)
Slide 37
Presented By Usha Menon at 2015 ASCO Annual Meeting
![Page 11: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/11.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 12: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/12.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 13: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/13.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 14: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/14.jpg)
Initial Chemotherapy for Ovarian Cancer• 6 cycles taxane-platinum combination is standard• IP admin benefits patients with low volume (optimal) disease but
has increased toxicity– Surgical NED patients treated with IP have a median survival over 9 years
• Paclitaxel (taxol) and docetaxel (taxotere) equally effective in combination with carboplatin
• Weekly (dose-dense) paclitaxel improves outcome in JGOG study• GOG 262 confirms findings in suboptimal patients not receiving bevacizumab
• No current role for a third chemotherapeutic agent• Bevacizumab during and after chemotherapy improves PFS but not
OS• Pazopanib maintenance improves PFS, too early for OS.
![Page 15: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/15.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 16: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/16.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 17: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/17.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 18: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/18.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 19: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/19.jpg)
What is a clinical trial?• A clinical trial is any investigation of a new drug
or combination of drugs, clinical intervention, or treatment– New unapproved drugs– FDA approved drugs in new situations– New combinations
• All clinical trials involving human subjects are required to have Institutional Review Board (IRB) Approval– Retrospective trial– Prospective
![Page 20: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/20.jpg)
Why do we do clinical trials?
• To improve disease outcome• To decrease toxicity of treatment• To identify new, active drugs or drug combinations• To • Despite being “new” trial
is at the tail end of a long investigative process
– Paclitaxel:• Discovered 1967• Clinical trials late 80’s• Standard care mid 90’s
![Page 21: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/21.jpg)
Why Participate in a Clinical Trial?• Benefit to society
– Clinical trials have got us to where we are now!– Nationwide, only about 3% of patients with cancer
participate in clinical trials• Benefit to individual
– Trials are usually done with significant oversight and close clinical monitoring
– You may get a new, promising drugs years before FDA approval• many drugs are tested (and paid for) in clinical trials
– Most phase III trials are positive
![Page 22: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/22.jpg)
Clinical Study: Pluses• Access to new drugs & interventions• Close monitoring• Active role in health care• Among the first to benefit• Most Phase III trials are positive
![Page 23: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/23.jpg)
Clinical Study: Minuses• Logistics can be burdensome - less flexibility in
treatment and dose/schedule changes• Unknown side effects• New approach, may not work• Only 3% of patients with cancer are in trials
(higher in pediatrics)
![Page 24: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/24.jpg)
Considerations in the decision to participate in a clinical trial
How serious is your disease? What is the expected outcome with standard treatment? What are your other non-trial options? What is the standard of care? What toxicity does the standard of care have? What are the goals of the study?
Decrease toxicity? Improve efficacy?
![Page 25: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/25.jpg)
Considerations in the decision to participate in a clinical trial
What is being investigated? Is it a new agent A new way of using an approved agent?
What are the risks? What are the costs? What are the added logistics? What is in it for you? What is in it for future generations?
![Page 26: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/26.jpg)
Where are Clinical Trials Done?
• Large cancer center• University hospital• Local medical center or physician’s office
– NCI Community Clinical Oncology Program (CCOP)– NCI Community Oncology Research Program
(NCORP)
• Internationally
![Page 27: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/27.jpg)
Who Pays for Clinical Trials?• Private Foundations• Government
– Funding through grant mechanisms• Individual grants (R01)• Cooperative groups (NRG: NSABP, GOG, RTOG)• SPORE grants
• Industry– New drug approvals– New indications of approved drugs
![Page 28: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/28.jpg)
Types of Clinical Trials• Preclinical• Phase I – Goal: To define tolerable dose and schedule
– Primary endpoint is toxicity– Pro – usually open entry criteria (good for rare diseases)– Con - limited data and toxicity information on the treatment
• Phase II - Endpoint is response in a specific disease– Pro – dose and schedule defined, some data to suggest efficacy,
may get access to new drugs or treatments before approved– Con - barriers to entry are higher
• Phase III - Endpoint is comparison to current standard– Pro - May get better treatment– Con - may not get experimental arm, toxicity may be higher, may
not be as efficacious
![Page 29: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/29.jpg)
Why are Clinical Trials Critically Important for the Future of Cancer Care?
- The best treatment is often poorly understood.- Access to novel, cutting-edge treatments.- Advancing cancer care is a dual effort from
researchers and patients alike.- Patient empowerment and involvement- Care on a clinical trial is often more structured
for patients. - The goal of improving patient results and
quality of life REQURES clinical trials
![Page 30: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/30.jpg)
When is it appropriate to consider a clinical trial?
• You must be eligible, no exceptions• Treatment
– Something new or investigational, not otherwise available to you
– A treatment that might expand your options– A treatment that might result in less toxicity– Treatment in a situation that might not ordinarily
be treated• It needs to “feel right” to you
– You and your physician must be comfortable with all of the options on the trial
• Don’t be scared off by consent forms, read them, review them with your doctor and your family
![Page 31: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/31.jpg)
Patient Misconceptions About Clinical Trials
• Clinical trials are a last resort and are only offered to patients who have no hope of responding to “standard” therapy
• Clinical trials are for rare types of cancer• I can go on a clinical trial any time• If my doctor offers me a clinical trial, it is an indication
that (s)he doesn’t think I have long to live
![Page 32: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/32.jpg)
What can YOU do?!
• Help raise awareness– Join advocacy groups
• Be politically active!– Lobby for increased research funding for ovarian
cancer• Participate in clinical trials• Support foundations that support women’s
cancer research
![Page 33: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/33.jpg)
Motto & Take Home Message…
Research
Cures
Cancer!National Coalitio
n for Cancer ResearchBasic Science Translational Medicine
Screening & Prevention Therapeutics
![Page 34: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/34.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
![Page 35: NCCN Guidelines for Patients: Ovarian Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062223/5885a1b01a28abd2498b7313/html5/thumbnails/35.jpg)
© National Comprehensive Cancer Network, Inc. 2016, All rights reserved.The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
For more information on the NCCN Guidelines for Patients®
or the NCCN Foundation please contact [email protected]
or visit us at NCCN.org/Patients